NewAmsterdam Pharma (NASDAQ:NAMS) Issues Quarterly Earnings Results

Posted by Brian Himes on Aug 6th, 2026

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04), FiscalAI reports. The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $1.88 million. NewAmsterdam Pharma had a negative return on equity of 34.05% and a negative net margin of 3,644.21%.

Here are the key takeaways from NewAmsterdam Pharma’s conference call:

European regulatory progress: Obicetrapib received a positive CHMP recommendation, with EMA approval and Menarini-led launches in the U.K. and Germany anticipated by late Q4 2026.
PREVAIL remains the central catalyst. Management said blinded event rates are tracking favorably against BROADWAY and that an interim analysis could occur in Q1 2027, while retaining the option to continue the trial through the end of 2027 to maximize statistical power.
The company highlighted broad lipid effects beyond LDL reduction, including more than 40% LDL lowering with obicetrapib monotherapy, roughly 60% with the ezetimibe fixed-dose combination, substantial HDL increases, and reductions in Lp(a) and small LDL particles. These claims remain dependent on ongoing outcomes validation.
Commercial preparations are accelerating amid a growing lipid-treatment market, expanded treatment guidelines, and a large undertreated patient population. NewAmsterdam said it has more than $678 million in cash and has expanded its commercial and medical-affairs leadership ahead of potential launches.
The company is advancing additional programs, including RUBENS in patients with diabetes and metabolic syndrome, REMBRANDT for plaque imaging with the fixed-dose combination, and SPINOZA to evaluate Alzheimer’s-related biomarkers in APOE4 carriers. These programs could broaden differentiation but remain investigational and are not yet established clinical benefits.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded up $0.25 on Thursday, reaching $27.67. The company had a trading volume of 1,649,399 shares, compared to its average volume of 989,831. The firm’s 50-day moving average price is $31.64 and its two-hundred day moving average price is $32.56. NewAmsterdam Pharma has a 1 year low of $22.26 and a 1 year high of $42.21.

Wall Street Analysts Forecast Growth

NAMS has been the subject of a number of research reports. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Royal Bank Of Canada reduced their price target on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday. BMO Capital Markets began coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They set an “outperform” rating and a $58.00 price target on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.33.

View Our Latest Stock Report on NAMS

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 105,000 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $738,870.02. This trade represents a 81.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 210,000 shares of company stock worth $6,713,550. Corporate insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors have recently made changes to their positions in NAMS. Wells Fargo & Company MN grew its holdings in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. Empowered Funds LLC bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $85,000. Persistent Asset Partners Ltd purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth approximately $138,000. The Manufacturers Life Insurance Company lifted its stake in shares of NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares during the last quarter. Finally, Guggenheim Capital LLC purchased a new position in NewAmsterdam Pharma during the 4th quarter valued at $224,000. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

(Get Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.